MARKET

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
-0.050
-2.79%
After Hours: 1.700 -0.04 -2.30% 16:30 04/03 EDT
OPEN
1.800
PREV CLOSE
1.790
HIGH
1.800
LOW
1.680
VOLUME
59.41K
TURNOVER
--
52 WEEK HIGH
4.230
52 WEEK LOW
1.230
MARKET CAP
113.56M
P/E (TTM)
-2.8042
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average VTVT stock price target is 7.00 with a high estimate of 8.00 and a low estimate of 6.00.

EPS

VTVT News

More
  • Has vTv Therapeutics (VTVT) Outpaced Other Medical Stocks This Year?
  • Zacks · 03/12 16:30
  • How Triad's public companies fared during markets' troubling week
  • American City Business Journals · 03/02 13:10
  • Daily Insider Ratings Round Up 2/25/20
  • Seeking Alpha - Article · 02/28 04:57
  • How the Triad's publicly traded companies did on market's worst day in two years
  • American City Business Journals · 02/25 10:00

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About VTVT

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
More

Webull offers kinds of vTv Therapeutics Inc stock information, including NASDAQ:VTVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VTVT stock news, and many more online research tools to help you make informed decisions.